Reduced induction of Tregs and a decrease in Treg suppressive markers like CTLA-4, CD73, and membrane-bound TGFβ were also observed (NCT02124850).556 This suggests that Motolimod might help overcome immune suppression in cancer patients. Here, TGFB1 is linked to cancer.